The Thrombopoietin Receptor: Revisiting the Master Regulator of Platelet Production

Overview

Journal Platelets

Publisher Informa Healthcare

Specialty Hematology

Date 2021 Jun 7

PMID 34097561

Citations 16

Authors

Ian S Hitchcock

Maximillian Hafer

Veena Sangkhae

Julie A Tucker

Affiliations

Soon will be listed here.

Abstract

Thrombopoietin (TPO) and its receptor, MPL, are the primary regulators of platelet production and critical for hematopoietic stem cell (HSC) maintenance. Since TPO was first cloned in 1994, the physiological and pathological roles of TPO and MPL have been well characterized, culminating in the first MPL agonists being approved for the treatment of chronic immune thrombocytopenia in 2008. Dysregulation of the TPO-MPL signaling axis contributes to the pathogenesis of hematological disorders: decreased expression or function results in severe thrombocytopenia progressing to bone marrow failure, while hyperactivation of MPL signaling, either by mutations in the receptor or associated Janus kinase 2 (JAK2), results in pathological myeloproliferation. Despite its importance, it was only recently that the long-running debate over the mechanism by which TPO binding activates MPL has been resolved. This review will cover key aspects of TPO and MPL structure and function and their importance in receptor activation, discuss how these are altered in hematological disorders and consider how a greater understanding could lead to the development of better-targeted and more efficacious therapies.

Citing Articles

Lysosome targeted therapies in hematological malignancies.

Manivannan M, Peters A, Gibson S Front Oncol. 2025; 15:1549792.

PMID: 40066097 PMC: 11891156. DOI: 10.3389/fonc.2025.1549792.

A review on the functional characteristics of the c-Myeloproliferative Leukaemia (c-MPL) gene and its isoforms.

Hussain M, Das S, Kulkarni M, Laha S Cell Oncol (Dordr). 2024; 47(5):1607-1626.

PMID: 39283476 DOI: 10.1007/s13402-024-00988-w.

The oocyte microenvironment is altered in adolescents compared to oocyte donors.

Gokyer D, Akinboro S, Zhou L, Kleinhans A, Laronda M, Duncan F Hum Reprod Open. 2024; 2024(3):hoae047.

PMID: 39211054 PMC: 11361810. DOI: 10.1093/hropen/hoae047.

PI3K/HSCB axis facilitates FOG1 nuclear translocation to promote erythropoiesis and megakaryopoiesis.

Liu G, Hou Y, Jin X, Zhang Y, Sun C, Huang C Elife. 2024; 13.

PMID: 38757931 PMC: 11101173. DOI: 10.7554/eLife.95815.

Advances in hematopoietic stem cells ex vivo expansion associated with bone marrow niche.

Deng J, Tan Y, Xu Z, Wang H Ann Hematol. 2024; 103(12):5035-5057.

PMID: 38684510 DOI: 10.1007/s00277-024-05773-1.

References

Noris P, Marconi C, De Rocco D, Melazzini F, Pippucci T, Loffredo G . A new form of inherited thrombocytopenia due to monoallelic loss of function mutation in the thrombopoietin gene. Br J Haematol. 2017; 181(5):698-701. DOI: 10.1111/bjh.14694. View

Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour J, Ianotto J . Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2015; 127(3):333-42. DOI: 10.1182/blood-2015-07-661983. View

Tijssen M, Di Summa F, van den Oudenrijn S, Zwaginga J, van der Schoot C, Voermans C . Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia. Br J Haematol. 2008; 141(6):808-13. DOI: 10.1111/j.1365-2141.2008.07139.x. View

Dasouki M, Rafi S, Olm-Shipman A, Wilson N, Abhyankar S, Ganter B . Exome sequencing reveals a thrombopoietin ligand mutation in a Micronesian family with autosomal recessive aplastic anemia. Blood. 2013; 122(20):3440-9. PMC: 3829117. DOI: 10.1182/blood-2012-12-473538. View

Cornish N, Aungraheeta M, Fitzgibbon L, Burley K, Alibhai D, Collins J . Monoallelic loss-of-function THPO variants cause heritable thrombocytopenia. Blood Adv. 2020; 4(5):920-924. PMC: 7065488. DOI: 10.1182/bloodadvances.2019001293. View

Wendling F, Varlet P, Charon M, Tambourin P . MPLV: a retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice. Virology. 1986; 149(2):242-6. DOI: 10.1016/0042-6822(86)90125-x. View

Pikman Y, Lee B, Mercher T, McDowell E, Ebert B, Gozo M . MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006; 3(7):e270. PMC: 1502153. DOI: 10.1371/journal.pmed.0030270. View

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A . c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood. 2001; 97(1):139-46. DOI: 10.1182/blood.v97.1.139. View

10.

Hoffman R, Andersen H, Walker K, Krakover J, Patel S, Stamm M . Peptide, disulfide, and glycosylation mapping of recombinant human thrombopoietin from ser1 to Arg246. Biochemistry. 1996; 35(47):14849-61. DOI: 10.1021/bi961075b. View

11.

CSERHATI I, Kelemen E . Acute prolonged thrombocytosis in mice induced by thrombocythaemic sera; a possible human thrombopoietin; a preliminary communication. Acta Med Acad Sci Hung. 1958; 11(4):473-5. View

12.

Seo A, Ben-Harosh M, Sirin M, Stein J, Dgany O, Kaplelushnik J . Bone marrow failure unresponsive to bone marrow transplant is caused by mutations in . Blood. 2017; 130(7):875-880. PMC: 5561901. DOI: 10.1182/blood-2017-02-768036. View

13.

Defour J, Itaya M, Gryshkova V, Brett I, Pecquet C, Sato T . Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. Proc Natl Acad Sci U S A. 2013; 110(7):2540-5. PMC: 3574938. DOI: 10.1073/pnas.1211560110. View

14.

Matthews E, Thevenin D, Rogers J, Gotow L, Lira P, Reiter L . Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation. FASEB J. 2011; 25(7):2234-44. PMC: 3114528. DOI: 10.1096/fj.10-178673. View

15.

Zhang B, Ng D, Jones C, Oh S, Nolan G, Salehi S . A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia. Blood. 2011; 118(26):6988-90. DOI: 10.1182/blood-2011-10-386177. View

16.

Livnah O, Stura E, Middleton S, Johnson D, Jolliffe L, Wilson I . Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 1999; 283(5404):987-90. DOI: 10.1126/science.283.5404.987. View

17.

Gurney A, de Sauvage F, Moore M . Thrombocytopenia in c-mpl-deficient mice. Science. 1994; 265(5177):1445-7. DOI: 10.1126/science.8073287. View

18.

Gorby C, Bellon J, Wilmes S, Warda W, Pohler E, Fyfe P . Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses. Sci Signal. 2020; 13(649). PMC: 7685028. DOI: 10.1126/scisignal.abc0653. View

19.

Plo I, Bellanne-Chantelot C, Mosca M, Mazzi S, Marty C, Vainchenker W . Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis. Front Endocrinol (Lausanne). 2017; 8:234. PMC: 5600916. DOI: 10.3389/fendo.2017.00234. View

20.

Kuter D, Beeler D, Rosenberg R . The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A. 1994; 91(23):11104-8. PMC: 45175. DOI: 10.1073/pnas.91.23.11104. View